Elafibranor, now Iqirvo, wins FDA accelerated approval for PBC
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ipsen’s elafibranor as a second-line treatment for primary biliary cholangitis (PBC).
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ipsen’s elafibranor as a second-line treatment for primary biliary cholangitis (PBC).
One year of treatment with Viking Therapeutics’ candidate VK2809 safely and effectively reduces liver fat content, damage, and scarring in adults with nonalcoholic steatohepatitis…
An imaging technique called holomedicine helped surgeons in Singapore make sure they removed a part of a liver from a living adult donor that was…
Vir Biotechnology’s investigational therapy tobevibart, used alone or in combination with another company candidate called elebsiran, can reduce hepatitis D virus (HDV) levels and…
The first patient has been enrolled in WIND-PSC, a global study to track the natural course of primary sclerosing cholangitis (PSC) and generate real-world…
Note: This story was updated July 9, 2024, to clarify Livmarli is approved in the U.S. for all PFIC forms, but not recommended for a…
The HealthWell Foundation, a charity that helps people who can’t afford to pay their medical bills, has started a new fund to support those…
Physicians from the GI Alliance, the largest physician-led network of gastroenterologists in the U.S., are now actively prescribing Rezdiffra (resmetirom) to eligible people…
About one year of treatment with Livmarli (maralixibat) allows about a third of patients with Alagille syndrome to stop at least one other…
A test-and-treat strategy was effective at identifying and treating hepatitis C among migrants and refugees in Italy coming from low-income countries where the condition…